A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3

Completed · Phase 2

Conditions studied: HIV Infections

In brief

To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.

Key facts

Study ID

NCT00002106

Run by

Glaxo Wellcome

People needed

104

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• Asymptomatic HIV-1 infection.
• CD4 count of 400-700 cells/mm3.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Significant illness.
• Acute illness at randomization.
• Hemodialysis.
• Prior Medication:
• Excluded:
• Antiretroviral use within 60 days prior to study entry.

Where it is running

• Pacific Oaks Med Group — Sherman Oaks, California, United States
• Community Research Initiative — Coral Gables, Florida, United States
• Duke Univ Med Ctr — Durham, North Carolina, United States
• Houston Clinical Research Network — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.